Sorted By Test Name - Mayo Medical Laboratories

HBAB
8254
variability in HBIG dosage required to achieve desirable serum anti-HBs levels among transplant
recipients during the first few weeks to months after transplantation. Patients who were hepatitis B
envelope (HBe) antigen positive before transplantation usually require more HBIG to achieve the target
anti-HBs levels, especially in the first week after transplantation. Duration of HBIG therapy varies from 6
months to indefinite among different US liver transplant programs. Protocols providing 500 mIU/mL during the first week after transplantation, >250
mIU/mL during weeks 2 to 12, and >100 mIU/mL after week 12. See HBV Infection-Monitoring Before
and After Liver Transplantation in Special Instructions.
Reference Values:
Negative
Clinical References: 1. Samuel D: Management of hepatitis B in liver transplant patients. Semin
Liver Dis 2004;24(suppl 1):55-62 2. Terrault NA, Vyas G: Hepatitis B immune globulin preparations and
use in liver transplantation. Clin Liver Dis 2003;7:537-550 3. Lok AS: Prevention of recurrent hepatitis B
post-liver transplantation. Liver Transpl 2002;8:S67-S73
Hepatitis B Surface Antibody, Qualitative/Quantitative, Serum
Clinical Information: Hepatitis B virus (HBV) infection, also known as serum hepatitis, is endemic
throughout the world. The infection is spread primarily through percutaneous contact with infected blood
products, eg, blood transfusion and sharing of needles by drug addicts. The virus is also found in virtually
every type of human body fluid and has been known to be spread through oral and genital contact. HBV
can be transmitted from mother to child during delivery through contact with blood and vaginal
secretions, but is not commonly transmitted via the transplacental route. The incubation period for HBV
infection averages 60 to 90 days (range of 45-180 days). Common symptoms include malaise, fever,
gastroenteritis, and jaundice (icterus). After acute infection, HBV infection becomes chronic in 30% to
90% of infected children or =5 years of age.
Some of these chronic carriers are asymptomatic, while others progress to chronic liver disease, including
cirrhosis and hepatocellular carcinoma. Hepatitis B surface antigen (HBsAg) is the first serologic marker,
appearing in the serum 6 to 16 weeks following HBV infection. In acute cases, HBsAg usually disappears
1 to 2 months after the onset of symptoms with the appearance of hepatitis B surface antibody (anti-HBs).
Anti-HBs also appears as the immune response following hepatitis B vaccination. See The Laboratory
Approach to the Diagnosis and Monitoring of Hepatitis B Infection in Publications and HBV
Infection–Diagnostic Approach and Management Algorithm in Special Instructions.
Useful For: Identifying previous exposure to hepatitis B virus Determining adequate immunity from
hepatitis B vaccination
Interpretation: This assay provides both qualitative and quantitative results. Positive results usually
indicate recovery from acute or chronic hepatitis B virus (HBV) infection, or acquired immunity from
HBV vaccination. Positive results (quantitative hepatitis B surface antibody [anti-HBs] levels of > or =12
mIU/mL) indicate an adequate immunity to hepatitis B from previous HBV infection or HBV vaccination.
Negative results (quantitative anti-HBs levels of or =5-12 mIU/mL) indicate inability to determine if
anti-HBs is present at levels consistent with recovery or immunity. Repeat testing is recommended in 1 to
3 months. See The Laboratory Approach to the Diagnosis and Monitoring of Hepatitis B Infection in
Publications and HBV Infection-Diagnostic Approach and Management Algorithm in Special
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 891